Literature DB >> 19543429

Diagnosis and management of benign prostatic hyperplasia in primary care.

Simon Tanguay1, Murray Awde, Gerald Brock, Richard Casey, Joseph Kozak, Jay Lee, J Curtis Nickel, Fred Saad.   

Abstract

Benign prostatic hyperplasia (BPH), and its clinical manifestation as lower urinary tract symptoms (LUTS), is a major health concern for aging men. There have been significant advances in the diagnosis and treatment of BPH in recent years. There has been a renewed interest in medical therapies and less invasive surgical techniques. As a consequence, the treatment needs of men with mild to moderate LUTS without evidence of prostate cancer can now be accomplished in a primary care setting. There are differences in the way urologists and primary care physicians approach the evaluation and management of LUTS due to BPH, which is not reflected in Canadian Urological Association (CUA) and American Urological Association (AUA) guidelines. A "shared care" approach involving urologists and primary care physicians represents a reasonable and viable model for the care of men suffering from LUTS. The essence of the model centres around educating and communicating effectively with the patient on BPH. This article provides primary care physicians with an overview of the diagnostic and management strategies outlined in recent CUA and AUA guidelines so that they may be better positioned to effectively deal with this patient population. It is now apparent that we must move away from the urologist as the first-line physician, and allow primary care physicians to accept a new role in the diagnosis and management of BPH.

Entities:  

Year:  2009        PMID: 19543429      PMCID: PMC2698785          DOI: 10.5489/cuaj.1116

Source DB:  PubMed          Journal:  Can Urol Assoc J        ISSN: 1911-6470            Impact factor:   1.862


  38 in total

Review 1.  Managing enlarged prostate in primary care.

Authors:  M J Naslund; F J Costa; M M Miner
Journal:  Int J Clin Pract       Date:  2006-12       Impact factor: 2.503

Review 2.  Pygeum africanum for benign prostatic hyperplasia.

Authors:  T Wilt; A Ishani; R Mac Donald; I Rutks; G Stark
Journal:  Cochrane Database Syst Rev       Date:  2002

3.  Serum prostate specific antigen is a strong predictor of future prostate growth in men with benign prostatic hyperplasia. PROSCAR long-term efficacy and safety study.

Authors:  C G Roehrborn; J McConnell; J Bonilla; S Rosenblatt; P B Hudson; G H Malek; P F Schellhammer; R Bruskewitz; A M Matsumoto; L H Harrison; H A Fuselier; P Walsh; J Roy; G Andriole; M Resnick; J Waldstreicher
Journal:  J Urol       Date:  2000-01       Impact factor: 7.450

4.  Quality-of-life impact of lower urinary tract symptom severity: results from the Health Professionals Follow-up Study.

Authors:  Garry Welch; Katie Weinger; Michael J Barry
Journal:  Urology       Date:  2002-02       Impact factor: 2.649

5.  Serenoa repens extract for benign prostate hyperplasia: a randomized controlled trial.

Authors:  K E Willetts; M S Clements; S Champion; S Ehsman; J A Eden
Journal:  BJU Int       Date:  2003-08       Impact factor: 5.588

Review 6.  Update on the diagnosis and management of prostate cancer.

Authors:  Mark LaSpina; Gabriel P Haas
Journal:  Can J Urol       Date:  2008-08       Impact factor: 1.344

Review 7.  Management of benign prostatic hyperplasia by the primary care physician in the 21st century: the new paradigm.

Authors:  Jack Barkin
Journal:  Can J Urol       Date:  2008-08       Impact factor: 1.344

Review 8.  Serenoa repens for benign prostatic hyperplasia.

Authors:  James Tacklind; Roderick MacDonald; Indy Rutks; Timothy J Wilt
Journal:  Cochrane Database Syst Rev       Date:  2009-04-15

Review 9.  A practical guide to the evaluation and treatment of male lower urinary tract symptoms in the primary care setting.

Authors:  M T Rosenberg; D R Staskin; S A Kaplan; S A MacDiarmid; D K Newman; D A Ohl
Journal:  Int J Clin Pract       Date:  2007-07-11       Impact factor: 2.503

10.  Comparison of digital rectal examination and serum prostate specific antigen in the early detection of prostate cancer: results of a multicenter clinical trial of 6,630 men.

Authors:  William J Catalona; Jerome P Richie; Frederick R Ahmann; M'Liss A Hudson; Peter T Scardino; Robert C Flanigan; Jean B DeKernion; Timothy L Ratliff; Louis R Kavoussi; Bruce L Dalkin; W Bedford Waters; Michael T MacFarlane; Paula C Southwick
Journal:  J Urol       Date:  1994-05       Impact factor: 7.450

View more
  13 in total

1.  The aging male population and medical care for benign prostatic hyperplasia in Canada.

Authors:  Nigel S B Rawson; Fred Saad
Journal:  Can Urol Assoc J       Date:  2010-04       Impact factor: 1.862

2.  MRI-based method for lower urinary tract dysfunction in adult male mice.

Authors:  Dalton T McLean; David R Rutkowski; Teresa Liu; Diego Hernando; William A Ricke; Alejandro Roldán-Alzate
Journal:  Am J Clin Exp Urol       Date:  2019-06-15

3.  Drug-induced orthostatic hypotension: A systematic review and meta-analysis of randomised controlled trials.

Authors:  Cini Bhanu; Danielle Nimmons; Irene Petersen; Mine Orlu; Daniel Davis; Hajra Hussain; Sanuri Magammanage; Kate Walters
Journal:  PLoS Med       Date:  2021-11-09       Impact factor: 11.069

Review 4.  Role of prostate stem cells and treatment strategies in benign prostate hyperplasia.

Authors:  Kalyan J Gangavarapu; Peter F Jowdy; Barbara A Foster; Wendy J Huss
Journal:  Am J Clin Exp Urol       Date:  2022-06-15

5.  Benign prostatic hyperplasia: An overview of existing treatment.

Authors:  Neelima Dhingra; Deepak Bhagwat
Journal:  Indian J Pharmacol       Date:  2011-02       Impact factor: 1.200

6.  Impact of oral capsule of Peganum harmala on alleviating urinary symptoms in men with benign prostatic hyperplasia; a randomized clinical trial.

Authors:  Majid Shirani-Boroujeni; Saeed Heidari-Soureshjani; Zahra Keivani Hafshejani
Journal:  J Renal Inj Prev       Date:  2016-12-18

7.  Anti-Proliferative Effects of HBX-5 on Progression of Benign Prostatic Hyperplasia.

Authors:  Bo-Ram Jin; Hyo-Jung Kim; Sang-Kyun Park; Myoung-Seok Kim; Kwang-Ho Lee; Il-Joo Yoon; Hyo-Jin An
Journal:  Molecules       Date:  2018-10-14       Impact factor: 4.411

8.  Electroacupuncture for moderate and severe benign prostatic hyperplasia: a randomized controlled trial.

Authors:  Yang Wang; Baoyan Liu; Jinna Yu; Jiani Wu; Jing Wang; Zhishun Liu
Journal:  PLoS One       Date:  2013-04-12       Impact factor: 3.240

9.  Clinical effects of discontinuing 5-alpha reductase inhibitor in patients with benign prostatic hyperplasia.

Authors:  Won Kim; Jae Hung Jung; Tae Wook Kang; Jae Mann Song; Hyun Chul Chung
Journal:  Korean J Urol       Date:  2014-01-15

10.  HBX-6, Standardized Cornus officinalis and Psoralea corylifolia L. Extracts, Suppresses Benign Prostate Hyperplasia by Attenuating E2F1 Activation.

Authors:  Bo-Ram Jin; Hyo-Jung Kim; Jong-Hwan Seo; Myoung-Seok Kim; Kwang-Ho Lee; Il-Joo Yoon; Hyo-Jin An
Journal:  Molecules       Date:  2019-05-02       Impact factor: 4.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.